Arcturus Therapeutics

Pipeline

Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery. Arcturus’ versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S. and other countries). Arcturus’ proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company’s commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc. (A Johnson and Johnson Company) and Ultragenyx Pharmaceutical, Inc.

name

LUNAR-OTC

indication
OTC Deficiency
api
Nucleic Acid

INTERNAL mRNA PROGRAM

PRECLINICAL

name

LUNAR-RLD

indication
Rare Liver Disease
api
Nucleic Acid

INTERNAL mRNA PROGRAM

PRECLINICAL

name

LUNAR-HBV

indication
Hepatitis B
api
Nucleic Acid

PARTNERED PROGRAM

RESEARCH

name

LUNAR-TKD

indication
NASH
api
Nucleic Acid

PARTNERED PROGRAM

RESEARCH

name

LUNAR-RARE1

indication
Undisclosed Rare Disease
api
Nucleic Acid

PARTNERED mRNA PROGRAM

RESEARCH

name

LUNAR-RARE2

indication
Undisclosed Rare Disease
api
Nucleic Acid

PARTNERED mRNA PROGRAM

RESEARCH

name

LUNAR-CF

indication
Cystic Fibrosis
api
Nucleic Acid

INTERNAL mRNA PROGRAM

PRECLINICAL

name

LUNAR-RPL

indication
Vaccines
api
RNA Replicon

PARTNERED PROGRAM

RESEARCH

name

LUNAR-TTR

indication
TTR Amyloidosis - Partnering Discussions ongoing
api
Nucleic Acid

INTERNAL siRNA PROGRAM

PRECLINICAL

name

Arbutus, ARB-1467

indication
Hepatitis B
api
UNA Oligomers

PARTNERED PROGRAM

CLINICAL